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Abstract
With dengue virus (DENV) becoming endemic in tropical and subtropical regions worldwide,
there is a pressing global demand for effective strategies to control the mosquitoes that
spread this disease. Recent advances in genetic engineering technologies have made it
possible to create mosquitoes with reduced vector competence, limiting their ability to
acquire and transmit pathogens. Here we describe the development of Aedes aegypti mos-
quitoes synthetically engineered to impede vector competence to DENV. These mosquitoes
express a gene encoding an engineered single-chain variable fragment derived from a
broadly neutralizing DENV human monoclonal antibody and have significantly reduced viral
infection, dissemination, and transmission rates for all four major antigenically distinct
DENV serotypes. Importantly, this is the first engineered approach that targets all DENV
serotypes, which is crucial for effective disease suppression. These results provide a com-
pelling route for developing effective genetic-based DENV control strategies, which could
be extended to curtail other arboviruses.
Author summary
With limited success of traditional vector control methods to curb dengue infections and
more than half of the world’s population still at risk, there is a need for novel strategies to
reduce its impact on public health. Recent advances in genetic technologies has allowed
for precise modifications of mosquito genome to make them resistant to infections, thus
breaking the transmission cycle. Here we generated engineered Ae. aegypti mosquitoes
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efficiently expressing a DENV-targeting single-chain variable fragment (scFv) derived
from a previously characterized broadly neutralizing human antibody, which blocked
infection and transmission in these mosquitoes. To our knowledge, this is the first exam-
ple of an engineered transgene capable of rendering Ae. aegypti mosquitoes 100% refrac-
tory to all four serotypes of DENV. The engineered mosquitoes, in future, could easily be
paired with a gene drive, capable of spreading the transgene throughout wild disease-
transmitting mosquito populations and preventing further DENV transmission. Since a
number of diverse and well-characterized antibodies exist against other arboviruses (eg
chikungunya and Zika, this work also provides a proof-of-concept principle for develop-
ing similar genetic strategies for reducing the impact of these arboviruses.
Introduction
Dengue fever is a devastating viral disease caused by several antigenically distinct dengue viral
(DENV) serotypes that are all dangerous to humans but cannot be readily controlled using
broad-spectrum techniques [1,2]. Transmitted by infected mosquitoes, DENV infection typi-
cally manifests as severe fever, headaches, and myalgia[3] and can advance to the life-threaten-
ing dengue hemorrhagic fever and dengue shock syndrome[4]. Global incidences of DENV
and its associated economic burden have increased dramatically in recent years [5,6], with
over 50% of the world’s population now at risk of infection[7] and 390 million documented
infections per year[6] for an estimated $40 billion in economic losses annually[8,9]. Moreover,
there are currently no specific treatments nor preventive prophylactic measures [10] because
the single commercially available vaccine [11] is only partially effective [12], and due to
increased risk of severe dengue illness and hospitalization among certain groups, its use is pre-
vented in many contexts [13–15]. Therefore, control of the disease-spreading mosquitoes is
currently the best option for preventing DENV transmission [13].
Aedes aegypti [16], the main vector of DENV and other epidemiologically significant
viruses such as chikungunya (CHIKV), yellow fever (YFV), and Zika (ZIKV), is a domestic
endophilic mosquito[17] that has expanded its habitable range in recent decades[18] and will
likely continue to spread[19]. Current control measures including the removal of standing
water and the use of chemical insecticides have had limited success in reducing Aedes popula-
tions [20] and, thereby, incidences of DENV[21], and can instead cause insecticide resistance
and behavioral changes such as a shift in biting times[22,23]. Therefore, novel vector control
strategies[24], like the use of genetically modified mosquitoes to either suppress mosquito pop-
ulations or render mosquitoes unable to transmit pathogens[25], are increasingly needed. For
example, the development and deployment of a genetic Sterile Insect Technique (SIT)-like sys-
tem termed Release of Insect Dominant Lethal (RIDL) has had some success in reducing
Aedes mosquito populations in the wild[26,27]. Moreover, releases of mosquitoes artificially
infected with the intracellular endosymbiont Wolbachia, which can make infected males inca-
pable of successfully mating with uninfected females in an SIT-like manner and can inhibit
mosquito infection with pathogens such as DENV and ZIKV[28,29], have also been carried
out. These have been intended to either suppress mosquito populations or make them less
likely to transmit pathogens, and may hold promise for reducing the incidence of disease
[30,31]. However, these technologies require releases of large numbers of insects—and must
be carried out on an ongoing basis for RIDL and Wolbachia-based SIT—for continued vector
control, which is laborious and expensive.
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Therefore, there has been increasing interest in the development of engineered gene-drive
technologies, which are able to rapidly transmit themselves and any linked “cargo” genes, such
as anti-pathogen effectors, through wild disease-transmitting populations [25,32–35] such that
only a few releases of modest amounts of engineered insects could drive desirable cargo genes
through wild populations, making them efficient and cost effective for vector control. To
achieve disease reduction, such gene-drive systems need to be linked to useful “cargo”, such as
effective anti-pathogen genes, and several approaches for engineering Ae. aegypti resistance to
DENV have been attempted. For example, one study used RNA interference by employing
inverted RNA repeats to target DENV-2 in a conditional and tissue-specific manner[36,37],
while another described miRNA cassettes targeting DENV-3 that reduced viral transmission
rates[38]. In addition to using synthetic small RNAs, others have taken advantage of the mos-
quito’s innate antiviral JAK/STAT pathway to increase resistance to DENV-2 and DENV-4
[39]. However, all previous approaches have been limited by their ability to target only one or
two—not all four—major DENV serotypes. Because hyperendemicity of DENV in tropical
areas is frequent[5] and secondary DENV infection has been linked to severe dengue disease
(SDD), refractory mosquitoes should be capable of blocking all serotypes or risk being ineffec-
tive in controlling dengue epidemics. Therefore, better anti-DENV effectors are needed.
Broadly neutralizing antibodies may be especially promising as anti-DENV effector gene
candidates because of their ability to neutralize antigenically diverse viruses[40]. However,
while engineered monoclonal antibodies that confer resistance to Plasmodium, a protozoan
parasite that causes malaria, have been expressed in Anophelene mosquitoes[41–43], none tar-
geting a virus have been described in any mosquito species. Previously, a DENV-targeting
1C19 monoclonal antibody (MAb) was identified from a large panel of naturally occurring
MAbs from human subjects following vaccination or natural infection[44]. In vitro studies
demonstrated that this antibody neutralized viruses from all major DENV serotypes and was
capable of significantly reducing viremia in a mouse model after DENV-1 and DENV-2 infec-
tion[44]. Here, we engineer Ae. aegypti to express a 1C19-based, broadly neutralizing, single-
chain variable fragment (scFv) that is capable of neutralizing all four DENV serotypes[44].
Crucially, we demonstrate that mosquitoes expressing this anti-DENV scFv cannot be infected
with or transmit any of the four DENV serotypes and have few significant fitness costs con-
ferred by the presence of the antibody. These results provide a promising route for developing
effective DENV control strategies using genetically engineered mosquitoes.
Materials and methods
Anti-DENV scFv design
Sequences for the 1C19 variable heavy and light chains were obtained from hybridoma cells
expressing the human monoclonal antibody [44] that had been cloned biologically by flow
cytometry. RNA was extracted using the RNeasy kit (Qiagen #74104), and RT-PCR amplifica-
tion of antibody gene cDNAs was performed using primer sets designed to detect all human
antibody variable gene sequences [44]. The sequence of the antibody cDNAs was determined
by automated Sanger sequence analysis. The sequence analysis of the antibody variable gene
sequences in the cDNAs was performed using the international ImMunoGeneTics informa-
tion system (IMGT).
The variable regions of 1C19 were joined by a 15-amino-acid repeating glycine-serine [G
(4)S]3 linker[45] to encode a scFv form of the antibody[46]. These chain regions were codon
optimized for Ae. aegypti expression and then gene synthesized into a vector (GenScript, Pis-
cataway, NJ). For OA984-HA, a 3’ 30-amino-acid human influenza hemagglutinin (HA)
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epitope tag with a G(4)S linker[47] was added to the carboxy terminus of the single chain anti-
body for protein expression verification.
Plasmid assembly
To generate vector OA984 (the anti-DENV scFv-antibody transgene), several components
were cloned into the PiggyBac plasmid pBac[3xP3-DsRed] (a kind gift from R. Harrell) using
Gibson assembly/enzymatic assembly (EA) cloning [48]. First, a Drosophila codon-optimized
tdTomato marker was amplified with primers 984.1A and 984.1B (Supplementary S2 Table for
all primers) from a gene synthesized vector (GenScript, Piscataway, NJ) and cloned into a
XhoI/FseI-digested pBac[3xP3-DsRed] backbone using EA cloning. The resulting plasmid was
digested with AscI, and the following components were cloned in via EA cloning: the predicted
Ae. aegypti carboxypeptidase promoter [49] amplified from Ae. aegypti genomic DNA using
primers 984.2A and 984.2B, a GFP sequence amplified from vector pMos[3xP3-eGFP] [50]
with primers 984.3A and 984.3B, and a 677-bp p10 3’ untranslated region (UTR) amplified
with primers 984.4A and 984.4B from vector pJFRC81-10XUAS-IVS-Syn21-GFP-p10
(Addgene plasmid #36432). The anti-DENV scFv was then subcloned into the final vector
from a gene-synthesized plasmid (GenScript, Piscataway, NJ) using PmeI and PacI sites and
traditional ligation cloning. Annotated plasmid sequences and plasmid DNA are available via
Addgene (plasmid #120363).
To generate vector OA984-HA (anti-DENV scFv with HA-epitope tag), the G(4)S linker
and HAx3 tag were amplified with primers 984B.C1 and 984B.C2 from the ninaE[SBP-His]
vector containing these components [51] and cloned into the PacI digested OA984 backbone
using EA cloning. Annotated plasmid sequences and plasmid DNA are available via Addgene
(plasmid #120362). All primer sequences used to generate these plasmids are listed in S2
Table.
Generation of transgenic mosquitoes
Germline transformations were carried out largely as described [52]. Briefly, 0–1 hr old Higgs
wildtype (WT) Ae. aegypti pre-blastoderm embryos were injected with a mixture of vector
OA984 or OA984-HA (200 ng/μL) and a source of PiggyBac transposase (200 ng/μL)[50]; the
injected embryos were hatched in deoxygenated H2O. A total of 127 surviving WT adult G0
males and 115 surviving WT adult G0 females were recovered after the injection. Microin-
jected WT G0 adults were assigned to 48 pools and outcrossed to WT of the opposite sex in
medium-sized cages. Larvae were fed ground fish food (TetraMin Tropical Flakes, Tetra
Werke, Melle, Germany) and adults were fed with 0.3 M aqueous sucrose. Adult females were
blood fed three to five days after eclosion using anesthetized mice. All animals were handled in
accordance with the Guide for the Care and Use of Laboratory Animals as recommended by
the National Institutes of Health, and the methods were supervised by the local Institutional
Animal Care and Use Committee (IACUC). A total of 38,177 WT G1s were screened. G1 larvae
with strong positive fluorescent signals (3xp3-tdTomato) were selected under the fluorescent
stereomicroscope (Leica M165FC) and were separated into six individual groups characterized
by fluorescence patterning and intensity. One single transgenic male from each group was
then allowed to separately mate with 10 WT females to isolate each independent line. Three
independent lines, TADV-A (vector OA984), TADV-B (vector OA984-HA), and TADV-C
(vector OA984-HA) with the strongest fluorescence expression patterns were selected for fur-
ther characterization. To determine whether these lines represented single chromosomal inser-
tions, we backcrossed single individuals from each of the lines for four generations to WT
stock and measured the Mendelian transmission ratios in each generation; in all cases, we
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observed a 50% transmission ratio, indicating single-chromosome insertion. For one of the
three lines (TADV-A), transgenic mosquitoes were inbred for at least 20 generations to gener-
ate a homozygous stock. Mosquito husbandry was performed under standard conditions as
previously described [53].
Characterization of insertion sites
To characterize the insertion site of vector OA984 or OA984-HA in transgenic mosquitoes, we
adapted a previously described inverse polymerase chain reaction (iPCR) protocol [54] as fol-
lows. First, genomic DNA (gDNA) was extracted from 10 transgenic fourth instar larvae using
the DNeasy Blood & Tissue Kit (Qiagen #69504) per the manufacturer’s protocol. Two sepa-
rate restriction digests were performed on the gDNA (at 100 ng/μL) to characterize the 5’ and
3’ ends of the PiggyBac insertion using Sau3AI (5’ reaction) or HinP1I (3’ reaction) restriction
enzymes. A ligation step using NEB T4 DNA Ligase (NEB #M0202S) was performed on the
restriction digest products to circularize digested gDNA fragments, and two subsequent
rounds of PCR were carried out per ligation using the corresponding PiggyBac primers listed
in S3 Table. The final PCR products were cleaned up using the MinElute PCR Purification Kit
(Qiagen #28004) in accordance with the manufacturer’s protocol and were sequenced via
Sanger sequencing (Source BioScience, Nottingham, UK). To confirm the transgene insertion
locus and orientation via PCR, primers were designed based on iPCR-mapped genomic
regions and used in tandem with PiggyBac primers based on their location as listed in S3
Table. Sequencing data then was blasted to the AaegL5.0 reference genome [55]. The sequenc-
ing data was aligned with SeqManPro (DNASTAR, Madison, WI) to determine the orientation
of the transgene insertion site. Analysis of the sequencing data indicated that the insertion site
for TADV-A is on chromosome 2 (approximate position 310,340,476), the insertion site for
TADV-B is on chromosome 2 (approximate position 301,489,980), and the insertion site for
TADV-C is on chromosome 1 (approximate position 30,451,048) when aligned to the AaegL5
assembly (GenBank assembly accession: GCA_002204515.1)[56].
Total RNA extraction, isolation, and sequencing
Total RNA was extracted from the midguts of non-blood-fed and 24-hours post-blood-fed
TADV-A, TADV-B, TADV-C or WT adult females using the Ambion mirVana mRNA Isola-
tion Kit (ThermoFisher Scientific #AM1560). Following extraction, the RNA was treated with
Ambion Turbo DNase (ThermoFisher Scientific #AM2238). The RNA quality was assessed
using an RNA 6000 Pico Kit for Bioanalyzer (Agilent Technologies #5067–1513) and a Nano-
Drop 1000 UV-vis spectrophotometer (NanoDrop Technologies/Thermo Scientific, Wilming-
ton, DE). mRNA was isolated using an NEBNext Poly(A) mRNA Magnetic Isolation Module
(NEB #E7490), and libraries were constructed using an NEBNext Ultra II RNA Library Prep
Kit for Illumina (NEB #E7770). The libraries were quantified using a Qubit dsDNA HS Kit
(ThermoFisher Scientific #Q32854) and a High Sensitivity DNA Kit for Bioanalyzer (Agilent
Technologies #5067–4626) and sequenced on an Illumina HiSeq2500 in single-read mode
with a read length of 50 nt and sequencing depth of 30 million reads per library following the
manufacturer’s instructions. Reads were mapped to the Ae. aegypti genome (AaegL5.0) supple-
mented with the 1C19 cDNA sequence using STAR aligner [57], and the expression levels
were determined with featureCounts [58] (S4 Table). Correlation coefficients of the tran-
scripts-per-million (TPM) values between WT and transgenic animals were calculated in R
[14] and plotted with ggplot2 (S1 Fig). Differential expression analysis between transgenic and
WT sample pairs of the same feeding status (NBF or PBM) for each line using DESeq2 [59]
identified no significantly changed genes (padj < 0.05) for all six comparisons (data not
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shown). To increase the sensitivity of the assay, two factor analysis using both NBF and PBM
samples per line with design = ~ feeding + genotype was also performed and identified a num-
ber of differentially expressed genes for each line (S5 Table). However, expression of only nine
genes was consistently altered in all three lines (S6 Table), suggesting that expression of the
1C19 scFv transgene had minimal impact on overall expression patterns of endogenous genes.
All sequencing data can be accessed at NCBI SRA (study accession ID PRJNA524725).
Western blot assays
The general western blot protocol was adapted from CSH Protocols: SDS-PAGE of Proteins
[60]. Briefly, 5–7 days post eclosion, midguts from 25 non-blood-fed and 16-hour post-blood-
meal heterozygous TADV-A transgenic and WT mosquitoes were dissected and collected in
1x PBS. Protein samples from dissected tissues were extracted with ice-cold radioimmunopre-
cipitation assay buffer (RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.25% Na-deoxy-
cholate, 1% NP-40, 1 mM EDTA). The protein concentration was measured using Protein
Assay Dye (Bio-Rad, Cat. No#5000006) and multi-detection microplate readers (Molecular
Devices, SpectraMax M2). Next, 40 μg of total protein were run on a 12% SDS-PAGE and
transferred onto a 0.45 μm Immobilon-P Transfer Membrane (Merck Millipore, Cat.
NO#IPVH00010). The membrane was hybridized with a custom antibody at a 1 μg/mL dilu-
tion (GenScript, Item number: U3233DA170_2) to directly recognize the 1c19 scFv peptide
(26.3KDa) as well as a monoclonal antibody specific to the HA tag for lines TADV-B and C
(Cell Signaling, #3724S) at a 1:1,000 dilution; these were subsequently detected by using rabbit
IgG antibody (HRP) (GeneTex, Cat. No#GTX 213110–01) at a 1:10,000 dilution. Images were
generated by applying the chemiluminescent HRP substrate (Millipore, Cat. No#WBKLS0500)
to the blots.
DENV infection of mosquitoes and virus determination
All experiments were performed under biosafety level 3 (BSL-3) conditions in the insectary at
the Australian Animal Health Laboratory. The following DENV strains were used for all viral
challenge experiments: DENV-1 (isolate ET243, GenBank EF440432), DENV-2 (isolate
ET300, GenBank EF440433), DENV-3 (isolate ET209, GenBank EF440434), DENV-4 (isolate
ET288, GenBank EF440435). The virus was passaged in Vero cell monolayer cultures before
use for mosquito infections. WT or transgenic (confirmed by red fluorescence in the eye) mos-
quitoes were exposed to DENV as described previously [61]. Briefly, female mosquitoes were
challenged with an infected blood meal (TCID50 /mL) through membrane feeding using
chicken blood and skin. For infection frequency and virus titer, mosquito midguts were col-
lected at 4 dpi. For dissemination and transmission frequency, mosquito saliva, midguts, and
carcasses were collected at 14 dpi. Mosquito saliva was used to determine viral titers using a
TCID50 assay on Vero cell monolayer cultures. Midguts and carcasses were used to determine
the presence of viral RNA using RT-qPCR against NS5. Mosquito viral challenge, processing,
saliva testing, and molecular analyses of infection and dissemination were carried out as previ-
ously described [61]. DENV infection frequency was defined by the number of midguts (day
4) found positive for viral nucleic acid. Similarly, the dissemination frequency was calculated
by the number of carcasses (day 14) found positive by qPCR. Transmission frequency was
defined by the number of TCID50-positive saliva samples over the number tested. These differ-
ent frequencies and average TCID50 values were compared by the Student’s two-tailed t-test.
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Confirmation of transgene zygosity
Both homozygous and heterozygous (generated by crossing out homozygous individuals to
WT) mosquitoes were used for assays. To confirm the zygosity of tested transgenic mosqui-
toes, mosquito heads were homogenized using a bead-beater device for DNA extraction in
30 μL of extraction buffer (1x Tris-EDTA, 0.1 M EDTA, 1 M NaCl, and 2.5 μM proteinase K)
and incubated at 56˚C for 5 minutes and then at 98˚C for 5 minutes. The first round of PCR
was performed to test for the presence of the anti-DENV transgene using primers 991.3F1 and
1018.S19 (S3 Table). Another round of PCR was then performed using primers 1018.S19 and
1018.S21 (S3 Table) to amplify the WT insertion locus (i.e., locus lacking transgene insertion)
and thus determine zygosity. For TADV-B, primer set 991.3R2 and 1018.S73 was used to
amplify the anti-DENV transgene and primer set 1018.S73 and 1018.S74 were used to amplify
the WT insertion site. For TADV-C, primer sets 991.3F2 and 1018.S80 and set 1018.S80 and
1018.S82 were used to amplify the anti-DENV transgene and WT insertion site, respectively.
WT mosquitoes served as controls to ensure that the WT locus was successfully amplified in
the genetic background. A PCR kit (ThermoFisher Scientific #F553S) with a 57˚C annealing
temperature was used for all PCRs following standard protocols.
Generation of wMel Wolbachia line and infection assay
Eggs of Ae. aegypti infected with the Wolbachia strain wMel were obtained from the World
Mosquito Program (Prof. Scott O’Neill, Monash University). WT mosquitoes infected with
wMel were generated by crossing wMel+ females with males from the WT line, and the result-
ing offspring were used for DENV infection experiments. At the end of the experiment, the
Wolbachia infection status of these mosquitoes was tested using PCR with primers specific for
wMel detection [62] (S3 Table). The PCRs indicated the presence of wMel in>90% of mosqui-
toes, and only results from these positive mosquitoes were used for further analysis.
Fitness evaluation on transgenic anti-DENV mosquitoes
To determine if the anti-DENV transgene conferred a fitness cost, several fitness parameters
were evaluated in TADV-A transgenic heterozygous and sibling WT mosquitoes. The evalua-
tions of all experimental and control replicates were performed simultaneously. Insectary con-
ditions were maintained at 28˚C and 70 to 80% in relative humidity with a 12 hr light/dark
cycle. To assess the larval to pupal development time, the eggs were vacuum hatched, and the
larvae were distributed into pans (50 larvae per pan) containing 2.5 L of ddH2O and 0.6 mL of
fish food slurry. To determine the larval to pupal development time of transgenic and WT con-
trol mosquitoes, the larvae were allowed to pupate, and pupae were collected and counted
every day until no pupae were left. To assess female fertility and fecundity, 90 WT and trans-
genic females were mated to 20 WT males in a cage. After four days, the females were blood
fed and individually transferred into plastic vials filled with water and lined with egg paper.
After three days, egg papers were collected, and the eggs were counted and vacuum hatched in
nine-ounce plastic cups. Starting on the fourth day, the larvae were counted every day until no
larvae were present. Female fecundity refers to the number of eggs laid per female, and fertility
reflects the number of eggs hatching to produce larvae. To measure male mating success,
fecundity, and fertility, one TADV-A transgenic or WT male was mated to five WT females in
a single mesh-covered cup filled with water and lined with egg paper. Three days post blood
meal, the cups were checked for the presence of eggs, which were collected, counted, and
hatched. Hatched larvae were then counted every day until no larvae were present. Male mat-
ing success was calculated as the percentage of single male outcrosses that produced larvae.
Fecundity was measured as the number of eggs laid per cup; fertility was determined by the
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number of hatching larvae in each cup. Finally, to assess mosquito longevity, equal numbers of
male and female TADV-A transgenic or WT mosquitoes were placed in medium-sized cages
(in triplicate). Mosquitoes that died were counted and removed daily until all mosquitoes had
died. Statistical analyses were performed using GraphPad Prism software (GraphPad Software,
La Jolla, California, USA). The means were compared using unpaired t tests with Welch’s cor-
rection, with the exception of male mating success that did not use Welch’s correction. The
analyses of mosquito survivorship used the Mantel-Cox test. P values > 0.05 were considered
not significant.
Results
Generation of DENV-resistant mosquitoes
To determine whether expressing an anti-DENV antibody in mosquitoes could confer resis-
tance to DENV, we first needed to engineer a broadly neutralizing antibody that was compati-
ble with mosquitoes and could be expressed in vivo in its desired form. We chose 1C19 as our
model due to its ability to cross-neutralize multiple DENV serotypes in humans[44]. As it is a
human monoclonal antibody, however, it cannot be unobtrusively expressed in mosquitoes, so
a new form that is both compatible with mosquitoes and maintains its neutralization capabili-
ties had to be designed. We then choose to engineer an scFv comprising the linked variable
heavy (VH) and light (VL) chains because this format removes the human-specific constant
region that could impart difficulties in a mosquito and it can be expressed in one “chunk” in
an organism without the need for additional in vivo processing. To do this, sequences for the
1C19 VH and VL chains were obtained from hybridoma cells expressing the human monoclo-
nal antibody[44]. We then engineered a scFv comprising the VH and VL domains of 1C19
linked using a 15-amino-acid repeating glycine-serine [G(4)S]3 linker[45] that was codon-
optimized for Ae. aegypti. We also engineered a version of this 1C19 scFv that was fused with a
3’ 30-amino-acid human influenza hemagglutinin (HA) epitope tag, commonly used as a gen-
eral expression tag, reasoning that it might be useful in downstream expression analyses. To
conditionally drive expression of the 1C19 scFvs in the midgut of female mosquitoes following
a blood meal, which would ensure 1C19 expression any time the mosquito was in contact with
DENV, we used the Ae. aegypti carboxypeptidase (CP) promoter [49], which should induce
expression in the midgut following blood ingestion (Fig 1A). (Previous findings determined
that the CP promoter induces enhanced transcription of Aedes aegypti CPA mRNA after a
blood meal and a somewhat moderate expression in sugar-fed mosquitoes [63].)The engi-
neered anti-DENV transgenes (termed plasmid OA984 for the untagged version and plasmid
OA984-HA for the HA-tagged version) also contained an eye-specific 3xP3 promoter[64],
driving expression of tdTomato as a fluorescent transgenesis marker. Following the typical
transgenesis procedure in mosquitoes, consisting of embryonic microinjection and G0 out-
crossing, multiple independent transgenic lines (n = 6) were readily identified in the G1 gener-
ation via the robust expression of tdTomato fluorescence; three of the lines with the strongest
marker expression (termed Transgenic Anti-DENV [TADV]-A, containing OA984; and
TADV-B and C, containing OA984-HA) were selected for further experiments. We carried
out inverse PCR (iPCR) on genomic DNA extracted from the transgenic mosquitoes to verify
the transgene insertion site and performed backcrosses to WT for multiple generations to
ensure that the transgenic lines represented single chromosomal insertions, and were able to
confirm that, in all three independent lines, the anti-DENV transgenes were stably integrated
into single chromosomes.
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Fig 1. Effect of anti-dengue virus (DENV) single-chain variable fragment (scFv) on DENV titers of TADV-A, Wolbachia-infected (wMel), and
wildtype (WT) mosquitoes. (A) Schematic of experiment. TADV-A mosquitoes were generated via transgenesis with the anti-DENV construct, and
TADV-A, wMel, and WT mosquitoes were then challenged with a blood meal infected with one of four DENV serotypes (DENV-1, isolate ET243;
DENV-2, isolate ET300; DENV-3, isolate ET209; or DENV-4, isolate ET288). After the infected blood meal enters the mosquito midgut, there are
two potential outcomes: in the first (applies for all tested strains), the virus replicates and disseminates past the midgut to become transmissible; in
the second (applies to TADV-A mosquitoes), the anti-DENV transgene expresses scFv antibodies in the midgut that bind to the virus and neutralize
it. (B) Plots depicting viral titers. To determine if the anti-DENV transgene confers resistance to all four DENV serotypes, we determined viral titers
in extracted midguts, carcasses, and saliva from WT, TADV-A (homozygous [Hm] and heterozygous [Ht]), and wMel infected mosquitoes. Viral
genome equivalents (GE) from mosquito midguts (at 4 days post infection [dpi]) and carcass (at 14 dpi) were determined using RT-qPCR and
calculated using previously published methods. Viral titers in the saliva were determined using the median tissue culture infective dose (TCID50) on
Vero cells. For each experiment, data from three replicates is pooled. Red horizontal bars represent the mean GE/viral titer. ��p< 0.001.
https://doi.org/10.1371/journal.ppat.1008103.g001
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Expression of 1C19 scFv antibody
Robust expression and processing of 1C19 scFv transcripts is required for proper neutraliza-
tion of DENV, and it is important to know if such expression perturbs global gene-expression
patterns, which might interfere with the fitness of the mosquito. To confirm this, we sequenced
total RNA populations from dissected midgut tissues isolated from both blood-fed and non-
blood-fed female Higgs wildtype (WT) or TADV-A, B, or C mosquitoes using an Illumina
platform. We detected robust expression of the 1C19 scFv mRNA in both non-blood-fed and
24-hour post-blood-fed transgenic mosquitoes of all three lines, with clearly increased expres-
sion levels at 24-hours post-blood meal, while no expression was observed in the midguts of
female WT mosquitoes, suggesting that expression of the 1C19 scFv antibody is transgene-
dependent and blood-meal-inducible (~2.35–14.45 fold) as was intended. Importantly, while
there were some changes in expression of some genes in transgenic mosquitoes when com-
pared to WT, these represented a small fraction of the genome and, with a few exceptions, did
not appear to be consistent between the three transgenic lines (S5 and S6 Tables). This suggests
that the 1C19 scFv expression does not affect gene-expression patterns in a major, global way
(S1 Fig, S4–S6 Tables).
To confirm the proper expression of the 1C19 scFv, we performed western blots on dis-
sected midgut tissue from non-blood-fed and blood-fed WT and TADV-A as well as blood-
fed TADV-B and TADV-C female mosquitoes using either a custom anti-1C19 scFv antibody,
or an anti-HA antibody. Blot analyses revealed that the 1C19 scFv peptide was efficiently
expressed following a blood meal exclusively in transgenic mosquitoes (S2 Fig). Altogether,
these results suggest that the anti-DENV transgene is stably integrated into the mosquito
genome and that the DENV-targeting 1C19 antibody is expressed in an appropriate context
(i.e., in the midgut following a blood meal) for DENV suppression.
Engineered mosquitoes are resistant to infection with all four DENV
serotypes
To determine the functional significance of anti-DENV 1C19 scFv expression on vector com-
petence, the DENV-2 infection rates of the three transgenic TADV lines were first compared
to that of WT. To do this, adult females (WT or TADV-A, B, or C) were exposed to serotype
DENV-2 (isolate ET300, Genbank EF440433) via membrane blood feeding. At 4 days post
infection (dpi), midguts from blood-fed mosquitoes were dissected, and DENV RNA copies
were measured using RT-qPCR. All three lines showed a significant reduction in midgut infec-
tion rate (45 to 71%) and viral RNA levels (2 to 3 log lower) compared with WT control mos-
quitoes (infection rate 92%) (S3 Fig; S1 Table). Since no significant difference in DENV-2
midgut infection levels was detected between the three transgenic lines, TADV-A, which
exhibited the strongest antiviral phenotype (S3 Fig; S1 Table), was selected for further compre-
hensive characterization.
For a more detailed study of the TADV-A DENV vector competence, the effect of transgene
zygosity on the infection rate was determined by exposing additional adult females (WT or
TADV-A) to serotype DENV-2 and analyzing the dissected midguts at 4 dpi. Results from
three biological replicates revealed that none of the TADV-A mosquitoes homozygous for the
transgene (n = 35) were positive for DENV-2 infection in the midguts (Fig 1B). DENV-2 infec-
tion was detected in 85.4% (35/41) of the TADV-A mosquitoes that were heterozygous for the
transgene; however, these mosquitoes had significantly (p< 0.001) lower (~3 log10) viral RNA
levels (8.20 x 101 genome equivalent [GE]) than the WT (4.25 x 104 GE) (Fig 1B, Table 1).
To assay for viral dissemination to the rest of the mosquito body, total RNA was collected
from whole TADV-A mosquito carcasses (without midguts) and dissected midguts from both
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homozygous and heterozygous mosquitoes at 14 dpi. The results from three biological repli-
cates indicated that none of the homozygous TADV-A mosquitoes (n = 30) were positive for
viral replication (dissemination) in either the midgut or the midgut-free carcass (Fig 1B,
Table 1). DENV-2 prevalence was detected in 86.6% (26/30) of heterozygous TADV-A mos-
quitoes in both the carcass and midgut; however, they also had significantly (p< 0.001) lower
levels of viral RNA (~3 log10) compared to the WT (Fig 1B, Table 1). Finally, as transmission
occurs through the saliva, viral transmission rates were determined by collecting the saliva
from individual mosquitoes at 14 dpi and measuring the DENV-2 titers using an assay for the
median tissue culture infective dose (TCID50). No DENV-2 was detected in the saliva of homo-
zygous TADV-A mosquitoes (n = 30) (Fig 1B), though it was detected in 83.3% (25/30) of het-
erozygous TADV-A mosquitoes; however, here again the DENV-2 titers were significantly
(p< 0.001) lower (3.56 x 102 TCID50/ml/mosquito) than the WT mosquitoes (2.70 x 105
TCID50/ml/mosquito) (Fig 1B, Table 1).
To determine whether the anti-DENV 1C19 scFv is broadly inhibitory for other DENV
serotypes, the vector competence of TADV-A mosquitoes was assessed using DENV-1 (isolate
ET243, GenBank EF440432), DENV-3 (isolate ET209, Genbank EF440434), and DENV-4 (iso-
late ET288, Genbank EF440435). Tests for infection, dissemination, and transmission were
Table 1. Anti-DENV scFv effect on DENV infection, dissemination, and transmission rates. DENV titers in WT, heterozygous and homozygous TADV-A (TAD-
V-AHt and TADV-AHm, respectively), and wMel mosquitoes following a blood meal infected with one of four DENV serotypes are shown. DENV GE from mosquito mid-
guts (at 4 or 14 dpi) and carcasses (14 dpi) of WT, TADV-A, and wMel (for DENV-2 only) mosquitoes were determined using RT-qPCR and calculated using previously
published methods. Viral titers in saliva collected from WT, TADV-A, and wMel mosquitoes at 14 dpi were determined using TCID50 on Vero cells.
DENV GE or viral titer on indicated dpi from specified tissue
(proportion of mosquitoes with detected virus; percentage of mosquitoes with detected virus)
DENV Serotype Strain 4 dpi 14 dpi
Midgut–
GE
Midgut–
GE
Carcass–
GE
Saliva–
viral titer
DENV-1
WT 5.70 x 103
(29/35; 83%)
3.80 x 105
(35/40; 88%)
4.80 x 105
(35/40; 88%)
3.04 x 105
(35/40; 88%)
TADV-AHt 5.00 x 10
1
(20/28; 71%)
3.70 x 102
(25/30; 83%)
2.40 x 102
(25/30; 83%)
2.50 x 102
(25/30; 83%)
TADV-AHm 0.00 x 10
1
(0/28; 0%)
0.00 x 101
(0/28; 0%)
0.00 x 101
(0/28; 0%)
0.00 x 101
(0/28; 0%)
DENV-2
WT 4.25 x 104 (34/40; 85%) 4.40 x 105
(40/46; 87%)
5.35 x 105
(40/46; 87%)
2.70 x 105
(38/46; 83%)
TADV-AHt 8.20 x 10
1
(35/41; 85.4%)
3.90 x 102
(26/30; 86.6%)
6.70 x 102
(26/30; 87%)
3.56 x 102
(25/30; 83.3%)
wMel 4.75 x 101 (43/48; 90%) 5.10 x 101
(38/48; 79%)
6.45 x 101 (38/48; 79%) 4.90 x 101
(35/48; 73%)
TADV-AHm 0.00 x 10
1
(0/35; 0%)
0.00 x 101
(0/30; 0%)
0.00 x 101
(0/30; 0%)
0.00 x 101
(0/30; 0%)
DENV-3
WT 1.80 x 104
(23/30; 77%)
2.90 x 105
(29/35; 83%)
3.50 x 105
(29/35; 83%)
2.90 x 105
(29/35; 83%)
TADV-AHt 3.60 x 10
1
(22/30; 73%)
1.58 x 102
(20/30; 66%)
1.60 x 102
(20/30; 67%)
1.33 x 102
(20/30; 67%)
TADV-AHm 0.00 x 10
1
(0/30; 0%)
0.00 x 101
(0/30; 0%)
0.00 x 101
(0/30; 0%)
0.00 x 101
(0/30; 0%)
DENV-4
WT 3.25 x 103 (25/30; 83%) 3.80 x 104
(25/32; 78%)
1.50 x 105
(25/32; 78%)
1.60 x 105
(25/32; 78%)
TADV-AHt 3.40 x 10
1
(22/30; 73%)
2.38 x 102
(19/28; 68%)
2.95 x 102
(19/28; 68%)
1.08 x 102
(19/28; 68%)
TADV-AHm 0.00 x 10
1
(0/27; 0%)
0.00 x 101
(0/28; 0%)
0.00 x 101
(0/28; 0%)
0.00 x 101
(0/28; 0%)
https://doi.org/10.1371/journal.ppat.1008103.t001
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carried out as above, and the results, presented together in Fig 1B and Table 1, were compara-
ble to those obtained with the DENV-2 serotype. In short, the TADV-A mosquitoes homozy-
gous for the transgene proved to be refractory to infection with all three additional serotypes
also showing no infection in their midguts at 4 dpi (DENV-1 n = 28; DENV-3 n = 30; DENV-
4 n = 27). Even at 14 dpi, there was no sign of viral replication in the midgut or carcass for all
tested specimens, and none of the saliva samples (DENV-1 n = 28; DENV-3 n = 30; DENV-4
n = 28) were positive for the virus. As with DENV-2, the mosquitoes heterozygous for the
transgene still tested positive for the virus in most specimens, though the overall DENV titers
were significantly lower than compared to the WT in all cases (Fig 1B; Table 1).
Engineered anti-DENV mosquitoes outperform Wolbachia
To compare the inhibitory effect of the anti-DENV 1C19 scFv to DENV inhibition through
Wolbachia[65–67] infection, we challenged WT mosquitoes infected with Wolbachia (wMel)
with DENV-2. Vector competence results revealed that midguts from mosquitoes infected
with Wolbachia had significantly (p< 0.001) reduced DENV-2 RNA levels (4.75 x 101 GE) at 4
dpi compared with the WT (4.25 x 104 GE) (Fig 1B, Table 1). Similarly, viral dissemination at
14 dpi was also reduced (p< 0.001) in wMel mosquitoes (~3 log10), and DENV titers in mos-
quito saliva at 14 dpi were significantly (p< 0.01) lower (~3 log10) in wMel mosquitoes (4.90 x
101 TCID50/ml/mosquito) than in the WT (2.70 x 10
5 TCID50/ml/mosquito) (Fig 1B, Table 1).
Importantly, a direct comparison revealed that the TADV-A mosquitoes are significantly
(p< 0.001) more effective as homozygotes, and similarly effective as heterozygotes, at blocking
DENV infection as Wolbachia-infected mosquitoes.
Transgene impact on fitness
To determine whether the anti-DENV 1C19 scFv had any significant fitness effects on trans-
genic mosquitoes, we assessed several fitness parameters including larval to pupal development
time, male and female fecundity and fertility, male mating success, and longevity (Table 2). No
significant differences were observed between WT and TADV-A mosquitoes when examining
male mating success and fecundity and fertility in both males and females (p> 0.05). However,
we noticed a significant difference in larval to pupal development times (p< 0.0001), with WT
mosquitoes developing, on average, 0.8 days faster than TADV-A mosquitoes. When assessing
mosquito survivorship, there was no significant difference between WT and TADV-A males
(p> 0.05; S4 Fig), though WT female mosquitoes lived, on average, 4.5 days longer than
TADV-A females (p< 0.05; S4 Fig). The longevity of infected mosquitoes was also assessed.
Transgenic, WT, or wMel mosquitoes were infected with four DENV serotypes and their sur-
vivorship was assessed 14 dpi (Table 2). No significant (p> 0.01) differences between WT and
TADV-A longevity upon infection with serotypes DENV-2, -3, and -4 were observed. How-
ever, there was a significant difference in survival upon infection with serotype DENV-1, with
a higher proportion of WT mosquitoes surviving at 14 dpi (p< 0.01; Table 2, S4 Fig). In addi-
tion, a significant difference in survival between wMel mosquitoes and WT and TADV-A
mosquitoes infected with serotype DENV-2 was observed (p< 0.0001; S4 Fig).
Discussion
Our results demonstrate that conditional expression of the anti-DENV 1C19 scFv renders
mosquitoes refractory to all four major DENV serotypes and therefore appears to be a potent
viral inhibition strategy. While mosquitoes homozygous for the anti-DENV 1C19 scFv showed
complete refractoriness to DENV infection, heterozygous mosquitoes were still partially
refractory to DENV infection, dissemination, and transmission, with significant, several
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orders-of-magnitude reductions in viral titers in the saliva. Given previous characterizations of
the 1C19 scFv antibody, we presume that it achieves this refractoriness because, when it is
secreted into the epithelium of the posterior midgut in mosquitoes [63], it binds to the exposed
fusion loop of DENV and inhibits the virus particle from releasing its genome into the cyto-
plasm for replication. Based on previous findings, it is likely that this significant reduction in
viral titers would be sufficient to render heterozygous mosquitoes unable to transmit DENV to
a susceptible host[68]. Though this remains to be demonstrated, our results show that hetero-
zygous 1C19 scFv antibody-expressing transgenic mosquitoes are just as efficient at viral sup-
pression as—and homozygous mosquitoes are significantly more efficient than—Wolbachia-
infected mosquitoes, which are currently being released for DENV control because they are
known to be refractory to DENV[65].
The difference in refractory levels in the homozygous versus heterozygous mosquitoes also
suggests that the refractory phenotype is particularly sensitive to scFv antibody expression lev-
els, a phenomenon previously observed with anti-malarial scFv transgenes [41] and anti-ZIKV
synthetic small RNA transgenes [69]. If this means that complete refractoriness is susceptible
to positional effects, e.g., not refractory when the scFv antibody transgene is expressed from a
different, possibly more weakly expressing genomic insertion position, the identification of
more robust midgut-specific promoters may help to ensure sufficiently high expression levels
from a single copy of the transgene regardless of insertion site, as can the use of multiple anti-
Table 2. Effect of anti-DENV scFv on fitness. Comparisons of several fitness parameters (left-most column) between WT (second column from left) and TADV-A mos-
quitoes (third column from left) suggest that there are few significant differences (right-most column) between the two groups, indicating that the anti-DENV scFv does
not have a major impact on mosquito fitness. The survivorship of infected and non-infected mosquitoes is also shown. The median survival in days was determined for
non-infected mosquitoes, and the percent of surviving mosquitoes separately infected by four DENV serotypes was assessed at 14 dpi.
Strain
Fitness Parameter WT
(N)
TADV-A
(N)
P-value
Female fecundityθ†§ 103.6 ± 3.8 (60; 6,213) 110.2 ± 4.4 (57; 5,756) 0.2578
Egg hatchabilityθk§ 67.5 ± 3.2 (60; 4,208) 61.0 ± 4.1 (57; 4,046) 0.2149
Male mating successθο¶ 93.00 ± 0.04 (43) 95.00 ± 0.04 (37) 0.7756
Male fecundityθlc 226.3 ± 15.7 (43; 9,730) 202.7 ± 17.2 (37; 7,318) 0.3141
Egg hatchabilityθⅢ§ 75.9 ± 4.5 (43; 7,558) 73.1 ± 3.9 (37; 5,624) 0.6260
Larval to pupal development in daysθ§ 6.70 ± 0.77 (1,322) 7.50 ± 0.09 (774) <0.0001
Female median survival in days†† 53 (122) 48.5 (128) 0.0129
Male median survival in days†† 14 (175) 14 (184) 0.1781
% Survival at 14 dpi with DENV-1‡†† 80.8 (26) 43.5 (23) 0.0086
% Survival at 14 dpi with DENV-2‡†† 72.7 (33) 69.2 (34) 0.6891
% Survival at 14 dpi with DENV-3‡†† 64.9 (37) 52.2 (46) 0.2679
% Survival at 14 dpi with DENV-4‡†† 41.3 (138) 48.8 (41) 0.7256
θMean ± SEM reported.
†Average number of eggs laid per female (Number of females scored; total number of eggs counted).
kPercentage of laid eggs that produced larvae (Number of females scored; total number of larvae counted).
οPercentage of single male outcrosses that gave rise to viable progeny.
lAverage number of eggs laid per single male outcross (Number of male outcrosses scored; total number of eggs counted).
ⅢPercentage of laid eggs that produced larvae per single male outcross (Number of male outcrosses scored; total number of larvae counted).
§Unpaired t test with Welch’s correction was used.
¶Unpaired t test was used to evaluate the statistical significance between the proportions of fertile males.
††Mantel-Cox test was used.
‡Percentage of infected mosquitoes surviving at 14 dpi.
https://doi.org/10.1371/journal.ppat.1008103.t002
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DENV scFv antibodies in a single transgene [41,43]. Additionally, while we observed no signif-
icant reduction in multiple fitness parameters in transgenic mosquitoes when compared to
WT, some differences in fitness were observed, and more extensive analyses on fitness of both
infected and uninfected transgenic heterozygotes and homozygotes (possibly after introgres-
sion with a field-collected mosquito strain) would have to be performed before use of such
mosquitoes in the field.
The strategy we describe here provides an efficient “cargo” gene that can be coupled with a
gene-drive system to reduce or eliminate the risk of DENV transmission by mosquitoes. In
fact, previous efforts have demonstrated effective Cas9-mediated homing-based gene drives in
malaria vectors [70–72], and even Ae. aegypti [34]. Additionally, since homing-based drive sys-
tems quickly convert heterozygotes to homozygotes [25], linking the anti-DENV 1C19 scFv
antibody described here to such a drive system could, in theory, rapidly convert wild mosquito
populations into transgenic homozygotes that would be completely resistant to DENV trans-
mission. Of paramount importance to the viability of such an approach is the evolutionary sta-
bility of the refractory transgene, specifically in terms of the likelihood of viral-resistant
evolution. Indeed, several studies have shown that, in some contexts, DENV can rapidly evolve
resistance in response to neutralizing antibodies [73,74], and this may be especially likely in
the TADV-A heterozygotes described in this study. However, this potentially can be managed
through the selection of antibodies with mechanisms/epitopes that minimize the chance of
evolved resistance and the use of a combination of distinct anti-DENV antibodies (many of
which have been described, e.g.,[44,73–76]), as well as a combination of antibody and non-
antibody based DENV refractoriness transgenes (e.g., [36,37]; [38]; [39])). The deployment of
such a pan-serotype-targeting strategy could serve as an effective component of a comprehen-
sive program to reduce the incidence and impact of DENV.
Due to similarities within viral families, this research could have far-reaching consequences
for rendering mosquitoes resistant to other arboviruses like ZIKV and CHIKV by using similar
genetic engineering strategies to develop scFv-based transgenes. Multiple potent antibodies
that effectively neutralize these various mosquito-borne viruses have also been identified in the
last decade[77–81]. Although not all of these will confer robust viral resistance when expressed
in vivo in mosquitoes, the availability of diverse, well-characterized antibodies of this sort,
largely as a result of antibody therapeutic development efforts[78], should allow for the identi-
fication of those that function within the desired context. Given the increasing incidence of
disease caused by these viruses and the resulting global health implications, such scFv-based
transgenes coupled with gene-drive systems[34] can provide an effective, sustainable, and
comprehensive strategy for reducing the impact of arboviral mosquito-borne diseases.
Supporting information
S1 Fig. Expression correlation analyses of gene expression levels (indicated by TPM [tran-
scripts per million] values) in dissected midgut tissues from WT or transgenic (TADV-A,
-B, or -C) mosquitoes without a blood meal (A) and 24 hours after a blood meal (B). The y-
axis corresponds to TPM values in WT samples, and the x-axis corresponds to TPM values in
respective transgenic samples. Blue-colored points represent endogenous genes, and red-col-
ored points represent the 1C19 scFv. Comparisons between WT and TADV samples suggest
that 1C19 scFv expression is transgene-dependent and does not appear to significantly affect
global expression levels of endogenous RNAs. Pearson correlation coefficients (r) between
gene expression levels in WT versus transgenic samples are reported in bold in their respective
graphs.
(TIF)
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S2 Fig. Western blot analyses to probe for the presence of the 1C19 scFv antibody protein
in WT and transgenic midgut samples. Western blots were carried out utilizing a custom
antibody specific for the 1C19 scFv protein, as well as an antibody to recognize the 3xHA tag,
on dissected midgut tissues from non-blood-fed or 16-hour post-blood-meal WT or TADV-A,
TADV-B, or TADV-C mosquitoes. An anti-GAPDH antibody was used as a control. The pres-
ence of a 26.3-kDa band confirms the expression of the 1C19 scFv protein in transgenic, but
not in WT, mosquito midgut samples. The presence of a 30 kDa band indicates the presence of
the 3xHA tag in TADV-B and TADV-C but not in WT or TADV-A mosquitoes.
(TIF)
S3 Fig. Effect of the anti-DENV scFv on DENV GE in three independent transgenic mos-
quito lines. DENV GE in WT and transgenic mosquito lines (TADV-A, TADV-B, or
TADV-C) following a blood meal infected with DENV-2 (ET300 strain) are shown. DENV GE
from mosquito midguts (at 4 dpi) of WT or transgenic mosquitoes were determined using
real-time qPCR and calculated using previously published methods. Circles represent WT
mosquitoes; black diamonds represent anti-DENV homozygous transgenic mosquitoes; red
colored diamonds represent anti-DENV heterozygous transgenic mosquitoes. Horizontal bars
represent the mean viral titer. The Mantel-Cox test was used for statistical analysis.
��p< 0.001.
(TIF)
S4 Fig. Survivorship curves for uninfected WT and TADV-A mosquitoes and for DENV-
infected WT, wMel, and TADV-A mosquitoes. The x-axis indicates the number of days
elapsed after the start of the experiment, and the y-axis indicates the percent of mosquitoes
surviving on each elapsed day. (A) For the uninfected panel, where the survivorship curves for
WT and TADV-A male and female mosquitoes are shown separately, each line represents the
accumulated results of 120–180 adult mosquitoes combined from 3 biological replicates. Sig-
nificant differences in survivorship were observed between WT and TADV-A females, with
WT females surviving, on average, 4.5 days longer (p� 0.01). (B) For the infected panels, WT,
wMel, and TADV-A females were given a blood meal infected with DENV-1, DENV-2,
DENV-3, or DENV-4 (as indicated on respective plot titles). The survivorship of infected mos-
quitoes was determined over the course of 14 days (the time it takes for the virus to dissemi-
nate past the midgut and eventually become transmissible). No significant differences in
survivorship were found between WT and TADV-A mosquitoes when infected with DENV-3
and DENV-4, but significant differences were observed upon infection with DENV-1, with
more WT mosquitoes (80%) surviving at 14 dpi than TADV-A mosquitoes (~40%; p� 0.01).
When infected with DENV-2, more wMel mosquitoes (>90%) survived at 14 dpi compared to
WT and TADV-A mosquitoes (both ~70%; p< 0.0001). The Mantel-Cox test was used to
determine statistical significance. �p� 0.01, ���p< 0.0001.
(TIF)
S1 Table. Effect of the anti-DENV scFv on DENV-2 GE in three independent mosquito
lines. DENV-2 GE are shown below for WT, TADV-A, TADV-B, and TADV-C mosquito
lines following a blood meal infected with the DENV-2 ET300 strain. Midgut samples were
collected 4 dpi, and GE were determined using real-time RT-qPCR and calculated using previ-
ously published methods.
(DOCX)
S2 Table. Primers utilized to generate anti-DENV scFv used in this study.
(DOCX)
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S3 Table. Diagnostic primers used for inverse PCR (iPCR) assays, zygosity confirmation,
pan-DENV serotype detection, and wMel infection confirmation.
(DOCX)
S4 Table. Quantification of total RNA expression in WT, TADV-A, TADV-B, and
TADV-C mosquito midguts prior to blood meal (NBF) and 24-hours post-blood feeding
(PBM). Both raw read counts and normalized TPM values are included.
(XLSX)
S5 Table. Differential RNA expression by a two-factor DESeq analysis in WT, TADV-A,
TADV-B, TADV-C mosquito midguts prior to blood meal (NBF) and 24-hours post-blood
feeding (PBM). Statistics such as p-value and p-adj are included. Gene expression changes (in
terms of log2FoldChange) describe the genes that are upregulated in either the WT (negative
values) or transgenic mosquitoes (positive values).
(XLSX)
S6 Table. List of genes showing consistently altered expression in transgenic (TADV-A,
TADV-B, and TADV-C) versus WT mosquito midguts. Only 9 genes were found to be con-
sistently upregulated in all three transgenic lines when compared to WT.
(XLSX)
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